Results from clinical trial of Hanmi's new drug (HM61713) were presented at ASCO

Hanmi pharmaceutical company announced on 3rd that phase II/III interim report of their targeted anti-cancer drug, HM61713, was presented at American Society of Clinical Oncology (ASCO) which was held from May 30th to June 3rd at Chicago, US.

HM61713 was selected as a subject to be presented at the symposium of lung cancer (title: EGFR targeted anti-cancer drug over next 10 years) and Professor Dong Wan Kim from the Oncology Department of Seoul National University Hospital announced the results.

According to their findings, HM61713, an anti-cancer drug that selectively inhibits mutation of EGFR (epidermal growth factor receptor) which participates on the growth of cancer, showed efficacy on disease control in 36 out of 48 (75%) patients with T790M mutation-positive lung cancer who had been tolerant with prior EGFR TKI treatment and showed an actual decrease in the size of tumor in 14 patients (29%).

“There had been a lot of progress on the treatment of lung cancer but we still need more efficient treatments.”, “The results from our clinical trial are significant since HM61714 has shown its possibility to overcome the tolerance of first generation EGFR TIK which is being used as the standard treatment line for patients with EGFR mutation-positive lung cancer.” said Professor Kim, the Head researcher.

Based on the results of this clinical trial, Hanmi pharmaceutical plans to initiate global Phase II of HM61713 in the second half of 2014.